Philogen Considers Partnering As Two Lead Assets Near Market
Bolstering Targeted Oncology Expertise
The Swiss-Italian biotech firm’s two lead assets for cancer are expecting pivotal readouts next year, prompting it to consider partnering strategies and further substantiating its targeted R&D approach.
